Category: Zacks Small Cap Research
By David Bautz, PhDNASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update Phase 3 Program for BXCL501 in Schizophrenia and Bipolar Disorder to Initiate Before End of 2019 On December 3, 2019, BioXcel Therapeutics, Inc. (NASDAQ:BTAI) announced ...
By John Vandermosten, CFANASDAQ::DYAI Dyadic (NASDAQ:DYAI) achieved an impressive milestone in its glycoengineering efforts which was announced via VTT’s1 presentation at the Protein and Antibody Engineering Summit (PEGS) Europe in Lisbon a few weeks ...
By David Bautz, PhDNASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Phase 3 Trial of SGX301 in CTCL Fully Enrolled; Data in 1Q20 On December 3, 2019, Soligenix, Inc. (NASDAQ:SNGX) announced that enrollment has completed in the Phase 3 c ...
By David Bautz, PhDNASDAQ:BVXV READ THE FULL BVXV RESEARCH REPORT Business Update Second Cohort of Phase 3 Trial Fully Enrolled On November 18, 2019, BiondVax Pharmaceuticals, Ltd. (NASDAQ:BVXV) announced that the second cohort of the Phase 3 trial o ...
By David Bautz, PhDTSX:ATE.V READ THE FULL ATE.V RESEARCH REPORT Business Update Phase 2b Study Results in 1Q20 In March 2019, Antibe Therapeutics Inc. (TSX:ATE.V) announced that the Phase 2b dose-ranging, efficacy study of ATB-346 had commenced. It ...
By John Vandermosten, CFAOTC:PMN.TO | OTC:ARFXF The Alzheimer’s Disease (AD) space has been on a wild ride over the last year with Biogen fishtailing like a Mustang on a wet Los Angeles freeway. During Phase II interim analysis Biogen’s AD drug BAN24 ...
By David Bautz, PhDNYSE:OGEN READ THE FULL OGEN RESEARCH REPORT Business Update Enrollment Complete for Phase 2 Trial of AGO13 in Oral Mucositis Oragenics, Inc. (NYSE:OGEN) is currently conducting a Phase 2 clinical trial of its lead development comp ...
By David Bautz, PhDTSX:MDNA.TO | OTC:MDNAF READ THE FULL MDNA.TO RESEARCH REPORT Business Update Additional P2b Data for MDNA55 Presented On November 25, 2019, Medicenna Therapeutics Corp. (TSX:MDNA.TO) (OTC:MDNAF) announced the presentation of addit ...
By Lisa ThompsonNASDAQ:TSEM READ THE FULL TSEM RESEARCH REPORT As the result of the corporate-wide strategy of Panasonic Corp. to purge its unprofitable businesses, Panasonic is selling all its semiconductor operations to Nuvoton Technology Corporati ...
By John Vandermosten, CFANASDAQ:HTBX READ THE FULL HTBX RESEARCH REPORT Heat Biologics, Inc. (NASDAQ:HTBX) reported third quarter 2019 results in a November 15 release following the submission of the companion 10-Q to the SEC the prior day. Since the ...